

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### **STA Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer that is responding to second or subsequent platinum-based chemotherapy**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### **Consultation**

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

It was raised during the scoping workshop that older people could have a potential communication problem with the clinicians and that this could affect the care provided. It was also clarified that this appraisal will look at people and not at women to account for gender reassignment.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

No potential equality issues were identified in the submissions, expert statements or academic report.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No other potential equality issues were identified by the Committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Not applicable

**Approved by Associate Director (name):** Janet Robertson.....

**Date:** 19/05/2015

## Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

During consultation a members of the public stated that negative guidance was an equalities issue because patients in the rest of Europe and the US would have access to olaparib, but not patients in the UK.

The Committee understood that this was not an equalities issue.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of STA Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer that is responding to second or subsequent platinum-based chemotherapy

Issue date: January 2016

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The summary table of the Appraisal Committees key conclusions specifies that no equalities issues were identified.

**Approved by Centre or Programme Director (name):** ...Meindert Boysen.....

**Date:** 16/11/2015